Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of Brca1-deficient mouse mammary tumors

ABSTRACT: RNAseq of Brca1-deficient mouse mammary tumors

PROVIDER: PRJNA625044 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

RNAseq of Brca1-deficient mouse mammary tumors

Project description:Brca1 mutation predisposes women to early onset of breast and ovarian cancers.Through its diverse functions in DNA damage repair, cell cycle control, transcription regulation, ubiquitination and so on, BRCA1 acts as a very significant tumor suppressor and genomic safeguard. Brca1 deficiency induces severe cellular stress, when occurring in the mammary glands, it impairs the regular developmental process and eventually causes tumorigenesis due to accumulation of genome instability and other mechanisms. The Brca1-defiencient mouse mammary tumor were characterized with great tumoral heterogeneity, which is in line with the human breast cancers carrying BRCA1 mutations. Here we studied the molecular complexicity of Brca1-deficient mouse mammary tumors vie RNA sequencing.

2021-11-17 | GSE148565 | GEO

Dropseq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

2021-11-17 | GSE148566 | GEO

Transcription profiling of spontaneous and transplanted topotecan-resistant BRCA1;P53-deficient mouse mammary tumors

Project description:Gene expression profiles of "spontaneous" and transplanted topotecan-resistant BRCA1;P53-deficient mammary tumors and their matched untreated controls

2010-01-05 | E-NCMF-28 | biostudies-arrayexpress

Single cell RNA-seq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

2021-11-17 | GSE148569 | GEO

Global Phosphoproteomics of BRCA1-deficient mammary tumors in genetic mouse models

Project description:The aim of the study is to identify differences in the global phosphoproteome across a BRCA1-deficient mouse mammary tumor panel. We have matched PARPi-naive and PARPi-resistant tumors, in which resistance was induced in vivo (mice bearing tumors were treated with PARPi untill the tumors stopped responding). Each pair of matched naive/resistant tumors originate from a different original tumor donor (one can consider each individual donor as an individual patient). From another analysis (RAD51 IRIF) we know that the mechanism of PARPi-resistance in a number of the tumors is driven by alterations in DNA damage response. Therefore, we can divide the tumors into four groups: (A) HR proficient, the exact mechanism not known, (B) HR proficient due to the loss of 53bp1 (TP53BP1), (C) HR proficient due to loss of Rev7 (MAD2L2) and (D) HR deficient, mechanism of resistance not known. Additionally, each tumor from our panel was retransplanted and challenged with 15 Gy irradiation to trigger a DNA damage response, therefore for each tumor we have an irradiated (IR) and a non-irradiated (NIR) sample. In this experiment each sample was processed in duplicate. Given all this, group (A) consists of 6 individual donors x 2 (matched naive/resistant) x 2 (NIR/IR) x 2 (duplicate) = 48 samples (samples 1-48); groups (B)-(D): 2 donors (per group) x 2 (naive/resistant) x 2 (NIR/IR) x 2 (duplicate) = 16 samples/group (B: samples 65-80, C: samples 81-96 and D: 49-64, according to the OPL label). In total this gives: 48 + 16 +16 +16 = 96 samples. Part of this analysis is used in the paper that also describes data from PXD031711

2022-06-06 | PXD032007 | Pride

Transcription profiling of Brca1- and p53-deficient mouse mammary tumors to treatment with doxorubicin, docetaxel or cisplatin

Project description:We have studied in vivo responses of spontaneous Brca1- and p53-deficient mouse mammary tumors to treatment with doxorubicin, docetaxel or cisplatin.

2007-06-18 | E-NCMF-5 | biostudies-arrayexpress

Dropseq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

Project description:Dropseq to study heterogeneity and tumorigenesis of Brca1-deficient mouse mammary tumors.

| PRJNA625043 | ENA

RNAseq data for mouse mammary tumors from three novel genetically engineered mouse models combining loss of Brca1, p53 and Rb supression

Project description:We have developed novel genetically engineered mouse mammary cancer models that develop hormone receptor-positive or -negative tumors depending on the combination of genetic abrrations induced in tumors. Tumors with loss of Brca1 and Trp53 are hormone receptor (HR) negative and tumors with or without Brca1 loss together with concomitant loss of Trp53 and inhibition of proteins of Rb family (Rbf) are HR positive. Transcriptome analysis revealed that HR-positive and -negative mammary tumors recapitulated human luminal and basal-like breast cancer expression signatures, respectively, confirming the histology-defined subtypes.

2022-11-04 | GSE206068 | GEO

Understanding BRCA1 function in INK4-RB deficient tumors

Project description:Understanding BRCA1 function in INK4-RB deficient tumors

| PRJNA655906 | ENA

The protein profile of mammary gland and tumors between Brca1-WT and MT miece by DIA-MS(DDA data)

Project description:WT mammary gland(WTMG),mutant-MG(MTMG),WT breast tumors(WTBT),MTBT and MTBT-adjacent MG were collected to do data-independent acquisiton(DIA)mass to find the intrinsic factors that is associated with Brca1-deficiency induced breast cancer.

2022-02-20 | PXD030355 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data